Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32327
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shuping, Joanna L | - |
dc.contributor.author | Matthews, Dawn C | - |
dc.contributor.author | Adamczuk, Katarzyna | - |
dc.contributor.author | Scott, David | - |
dc.contributor.author | Rowe, Christopher C | - |
dc.contributor.author | Kreisl, William C | - |
dc.contributor.author | Johnson, Sterling C | - |
dc.contributor.author | Lukic, Ana S | - |
dc.contributor.author | Johnson, Keith A | - |
dc.contributor.author | Rosa-Neto, Pedro | - |
dc.contributor.author | Andrews, Randolph D | - |
dc.contributor.author | Van Laere, Koen | - |
dc.contributor.author | Cordes, Lindsay | - |
dc.contributor.author | Ward, Larry | - |
dc.contributor.author | Wilde, Claire L | - |
dc.contributor.author | Barakos, Jerome | - |
dc.contributor.author | Purcell, Derk D | - |
dc.contributor.author | Devanand, Davangere P | - |
dc.contributor.author | Stern, Yaakov | - |
dc.contributor.author | Luchsinger, Jose A | - |
dc.contributor.author | Sur, Cyrille | - |
dc.contributor.author | Price, Julie C | - |
dc.contributor.author | Brickman, Adam M | - |
dc.contributor.author | Klunk, William E | - |
dc.contributor.author | Boxer, Adam L | - |
dc.contributor.author | Mathotaarachchi, Sulantha S | - |
dc.contributor.author | Lao, Patrick J | - |
dc.contributor.author | Evelhoch, Jeffrey L | - |
dc.date | 2023 | - |
dc.date.accessioned | 2023-03-22T01:49:30Z | - |
dc.date.available | 2023-03-22T01:49:30Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Alzheimer's & dementia (New York, N. Y.) 2023; 9(1): e12372 | en_US |
dc.identifier.issn | 2352-8737 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/32327 | - |
dc.description.abstract | The positron emission tomography (PET) radiotracer [18F]MK-6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity to medial temporal and neocortical NFTs, and low within-brain background. Objectives were to develop and validate a reproducible, clinically relevant visual read method supporting [18F]MK-6240 use to identify and stage AD subjects versus non-AD and controls. Five expert readers used their own methods to assess 30 scans of mixed diagnosis (47% cognitively normal, 23% mild cognitive impairment, 20% AD, 10% traumatic brain injury) and provided input regarding regional and global positivity, features influencing assessment, confidence, practicality, and clinical relevance. Inter-reader agreement and concordance with quantitative values were evaluated to confirm that regions could be read reliably. Guided by input regarding clinical applicability and practicality, read classifications were defined. The readers read the scans using the new classifications, establishing by majority agreement a gold standard read for those scans. Two naïve readers were trained and read the 30-scan set, providing initial validation. Inter-rater agreement was further tested by two trained independent readers in 131 scans. One of these readers used the same method to read a full, diverse database of 1842 scans; relationships between read classification, clinical diagnosis, and amyloid status as available were assessed. Four visual read classifications were determined: no uptake, medial temporal lobe (MTL) only, MTL and neocortical uptake, and uptake outside MTL. Inter-rater kappas were 1.0 for the naïve readers gold standard scans read and 0.98 for the independent readers 131-scan read. All scans in the full database could be classified; classification frequencies were concordant with NFT histopathology literature. This four-class [18F]MK-6240 visual read method captures the presence of medial temporal signal, neocortical expansion associated with disease progression, and atypical distributions that may reflect different phenotypes. The method demonstrates excellent trainability, reproducibility, and clinical relevance supporting clinical use. A visual read method has been developed for [18F]MK-6240 tau positron emission tomography.The method is readily trainable and reproducible, with inter-rater kappas of 0.98.The read method has been applied to a diverse set of 1842 [18F]MK-6240 scans.All scans from a spectrum of disease states and acquisitions could be classified.Read classifications are consistent with histopathological neurofibrillary tangle staging literature. | en_US |
dc.language.iso | eng | - |
dc.subject | Alzheimer's disease | en_US |
dc.subject | MK‐6240 | en_US |
dc.subject | [18F]MK‐6240 | en_US |
dc.subject | florquinitau | en_US |
dc.subject | neurofibrillary tangles | en_US |
dc.subject | positron emission tomography | en_US |
dc.subject | tau | en_US |
dc.subject | tracer | en_US |
dc.subject | visual read | en_US |
dc.title | Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Alzheimer's & Dementia (New York, N. Y.) | en_US |
dc.identifier.affiliation | Enigma Biomedical Group Toronto Ontario Canada. | en_US |
dc.identifier.affiliation | ADM Diagnostics, Inc. Northbrook Illinois USA. | en_US |
dc.identifier.affiliation | Clario, Inc. San Mateo California USA. | en_US |
dc.identifier.affiliation | Molecular Imaging and Therapy | en_US |
dc.identifier.affiliation | Department of Neurology The Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University New York New York USA. | en_US |
dc.identifier.affiliation | Department of Medicine Division of Geriatrics Alzheimer's Disease Research Center, University of Wisconsin Madison Wisconsin USA. | en_US |
dc.identifier.affiliation | ADM Diagnostics, Inc. Northbrook Illinois USA. | en_US |
dc.identifier.affiliation | The Gordon Center for Medical Imaging Department of Neurology Center for Alzheimer Research and Treatment Brigham and Women's Hospital Boston Massachusetts USA. | en_US |
dc.identifier.affiliation | Montreal Neurological Institute McGill University Montréal Quebec Canada. | en_US |
dc.identifier.affiliation | Nuclear Medicine and Molecular Imaging Department of Imaging and Pathology KU Leuven Leuven Belgium. | en_US |
dc.identifier.affiliation | StatKing Clinical Services Fairfield Ohio USA. | en_US |
dc.identifier.affiliation | The Florey Institute of Neuroscience and Mental Health | en_US |
dc.identifier.affiliation | Cerveau Technologies, Inc. Knoxville Tennessee USA. | en_US |
dc.identifier.affiliation | Department of Neurology The Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University New York New York USA. | en_US |
dc.identifier.affiliation | Columbia University Irving Medical Center Vagelos College of Physicians and Surgeons New York New York USA. | en_US |
dc.identifier.affiliation | Merck & Co., Inc. West Point Pennsylvania USA. | en_US |
dc.identifier.affiliation | Department of Radiology Athinoula A. Martinos Center for Biomedical Imaging Massachusetts General Hospital Harvard Medical School Charlestown Massachusetts USA. | en_US |
dc.identifier.affiliation | Department of Neurology The Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University New York New York USA. | en_US |
dc.identifier.affiliation | Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA. | en_US |
dc.identifier.affiliation | Department of Neurology Memory and Aging Center University of California San Francisco California USA. | en_US |
dc.identifier.affiliation | Enigma Biomedical Group Toronto Ontario Canada. | en_US |
dc.identifier.affiliation | Department of Neurology The Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University New York New York USA. | en_US |
dc.identifier.doi | 10.1002/trc2.12372 | en_US |
dc.type.content | Text | en_US |
dc.identifier.pubmedid | 36873926 | - |
dc.description.volume | 9 | - |
dc.description.issue | 1 | - |
dc.description.startpage | e12372 | - |
local.name.researcher | Rowe, Christopher C | |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.